Reports Q1 revenue $6.23M, consensus $5.88M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- De-Risked Phase 3 Design and Durable Efficacy Support Buy Rating on Stoke Therapeutics’ Zorevunersen
- Advancing Zorevunersen in Dravet Syndrome: Late‑Stage Trial Clarity and Regulatory Momentum Support Buy Rating on Stoke Therapeutics
- Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight
- Stoke Therapeutics price target raised to $60 from $36 at Canaccord
- Stoke Therapeutics files automatic mixed securities shelf